AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32710584 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine Dermis (PD)
Number of subjects: 30
Study 32710584 — intervention group
Group type: EXPERIMENTAL
Intervention: Polynucleotides-added Hyaluronic Acid (PAHA)
Number of subjects: 30
Study 32710584 — intervention group
Group type: COMPARATOR
Intervention: Polyurethane Foam (Control)
Number of subjects: 30
Study 34844756 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory markers (IL‐1ra, IL‐6, IL‐8, IL‐10, eotaxin, IP‐10, MCP‐1) measured at various time points (2, 12, 24, and 72 hours)
Number of subjects: 680
Study 33704540 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 SWs/min
Number of subjects: 75
Study 33704540 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 SWs/min
Number of subjects: 75
Study 33704540 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 SWs/min
Number of subjects: 75
Study 33704540 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency (60 SWs/min) may be more advantageous than intermediate (90 SWs/min) due to lower number of high energy shock waves causing less tissue damage; longer anesthesia time may be a disadvantage.
Number of subjects: 75
Study 35532113 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-custom mandibular advancement device (MAD) applied for 12 weeks
Number of subjects: 58
Study 35532113 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported outcomes for both custom and non-custom MADs
Number of subjects: 58
Study 33750355 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic Acid (FA) supplementation 400 μg/day from the 14th gestational week
Number of subjects: 68
Study 33750355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 32006633 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology delivered activity breaks (PAAC-R)
Number of subjects: 0
Study 32006633 — intervention group
Group type: COMPARATOR
Intervention: Classroom teacher delivered activity breaks (PAAC-T)
Number of subjects: 0
Study 35051669 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual fetal stimulation (abdominal stimulation when cervical dilatation <3 cm or vaginal stimulation when cervical dilatation ≥3 cm)
Number of subjects: 327
Study 35051669 — intervention group
Group type: COMPARATOR
Intervention: No stimulation
Number of subjects: 327
Study 34284778 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of malaria infections
Number of subjects: 240
Study 34284778 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of malaria
Number of subjects: 240
Study 34284778 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of first malaria
Number of subjects: 240
Study 34284778 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of first malaria in 6–59-month-olds
Number of subjects: 240
Study 34284778 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of first malaria in 5–17-year-olds
Number of subjects: 240
Study 34284778 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of first malaria in 18–45-year-olds
Number of subjects: 240
Study 34284778 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of first malaria with symptoms
Number of subjects: 240
Study 34284778 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of first malaria with symptoms in 6–59-month-olds
Number of subjects: 240
Study 34284778 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of first malaria with symptoms in 5–17-year-olds
Number of subjects: 240
Study 34284778 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of first malaria with symptoms in 18–45-year-olds
Number of subjects: 240
Study 34185013 — intervention group
Group type: EXPERIMENTAL
Intervention: SWAP IT intervention
Number of subjects: 3022
Study 34185013 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 3022
Study 32115759 — intervention group
Group type: EXPERIMENTAL
Intervention: cilofexor 100 mg
Number of subjects: 140
Study 32115759 — intervention group
Group type: EXPERIMENTAL
Intervention: cilofexor 30 mg
Number of subjects: 140
Study 32115759 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 140
Study 33037255 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyelid warming steamer (EWS) for 2 weeks
Number of subjects: 45
Study 34032286 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of rEPO (loading dose 2000 IU, infusion at 520 IU/h) from 6 to 72 h post-asphyxia
Number of subjects: 8
Study 34032286 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent rEPO boluses started 6 h after asphyxia
Number of subjects: 8
Study 34032286 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline or 5000 IU rEPO, with repeated doses every 48 h for 5 days
Number of subjects: 8
Study 32383503 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard face‐to‐face CBT plus mobile intervention (TCApp)
Number of subjects: 106
Study 32383503 — intervention group
Group type: COMPARATOR
Intervention: Standard face‐to‐face CBT only
Number of subjects: 106
Study 35778620 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) treatment for 7 days
Number of subjects: 89
Study 35778620 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) treatment
Number of subjects: 89
Study 33212205 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent behavioral intervention program including fluid intake prescription and adaptive behavioral interventions (financial incentives, structured problem solving, automated adherence interventions)
Number of subjects: 1642
Study 33212205 — intervention group
Group type: COMPARATOR
Intervention: Guideline-based fluid instructions
Number of subjects: 1642
Study 33028243 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated GP care plus treatment as usual
Number of subjects: 161
Study 33028243 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 161
Study 35398241 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg/day Zataria multiflora extract
Number of subjects: 41
Study 35398241 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg/day Zataria multiflora extract
Number of subjects: 41
Study 35398241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 34486305 — intervention group
Group type: EXPERIMENTAL
Intervention: KCl 0.45 g/polybag + T. asperellum 30 g/polybag (K3)
Number of subjects: 4
Study 34486305 — intervention group
Group type: EXPERIMENTAL
Intervention: KCl 0.15 g/polybag + T. asperellum 50 g/polybag (K1)
Number of subjects: 4
Study 34486305 — intervention group
Group type: EXPERIMENTAL
Intervention: KCl 0.30 g/polybag + T. asperellum 40 g/polybag (K2)
Number of subjects: 4
Study 34486305 — intervention group
Group type: EXPERIMENTAL
Intervention: KCl 0.60 g/polybag + T. asperellum 20 g/polybag (K4)
Number of subjects: 4
Study 34486305 — intervention group
Group type: EXPERIMENTAL
Intervention: KCl 0.75 g/polybag + T. asperellum 10 g/polybag (K5)
Number of subjects: 4
Study 34486305 — intervention group
Group type: COMPARATOR
Intervention: Without KCl fertilizer and T. asperellum (K0)
Number of subjects: 4
Study 35447154 — intervention group
Group type: EXPERIMENTAL
Intervention: Gigiigoo'inaan software intervention
Number of subjects: 0
Study 35447154 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 35179312 — intervention group
Group type: EXPERIMENTAL
Intervention: MADS technique
Number of subjects: 143
Study 35730664 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methotrexate (MTX) at a full dose of 0.3 mg/kg/week (maximum 25 mg/week) for 12 weeks
Number of subjects: 100
Study 35730664 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous methotrexate (MTX) at a full dose of 0.3 mg/kg/week (maximum 25 mg/week) for 12 weeks
Number of subjects: 100
Study 34147090 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum NT-proBNP levels on day 2-3 of life
Number of subjects: 52
Study 34147090 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum NT-proBNP levels on day 8-9 of life
Number of subjects: 52
Study 34147090 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of infants with hemodynamically significant PDA (hsPDA)
Number of subjects: 52
Study 34147090 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of hsPDA
Number of subjects: 52
Study 32167494 — intervention group
Group type: COMPARATOR
Intervention: Radial arterial catheter insertion site
Number of subjects: 7235
Study 32915000 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized response models (RRMs) with curtailed sampling
Number of subjects: 0
Study 32915000 — intervention group
Group type: EXPERIMENTAL
Intervention: Curtailed sampling
Number of subjects: 0
Study 36093907 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (8 g/d for 7 days)
Number of subjects: 8
Study 36093907 — intervention group
Group type: COMPARATOR
Intervention: Placebo (7 days)
Number of subjects: 8
Study 36093907 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 8
Study 32856181 — intervention group
Group type: EXPERIMENTAL
Intervention: Plate osteosynthesis with additional wire cerclage
Number of subjects: 16
Study 32856181 — intervention group
Group type: COMPARATOR
Intervention: Plate osteosynthesis without additional wire cerclage (control)
Number of subjects: 16
Study 32856181 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (comparison)
Number of subjects: 16
Study 36096651 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballroom dance (n = 23)
Number of subjects: 64
Study 36096651 — intervention group
Group type: EXPERIMENTAL
Intervention: Music (ukulele-playing, n = 17)
Number of subjects: 64
Study 36096651 — intervention group
Group type: COMPARATOR
Intervention: Social conversation (n = 24)
Number of subjects: 64
Study 34342026 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive left ventricular‐only fusion pacing (LVP)
Number of subjects: 63
Study 34342026 — intervention group
Group type: COMPARATOR
Intervention: Conventional biventricular pacing (BVP)
Number of subjects: 63
Study 33618033 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibromyalgia Integrative Training program for Teens (FIT Teens)
Number of subjects: 420
Study 33618033 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 420
Study 33618033 — intervention group
Group type: COMPARATOR
Intervention: Graded aerobic exercise (GAE)
Number of subjects: 420
Study 34174970 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aspirin
Number of subjects: 393
Study 34174970 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 393
Study 34174970 — intervention group
Group type: COMPARATOR
Intervention: Control (drug-free)
Number of subjects: 393
Study 36103181 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (200 mg/d)
Number of subjects: 173
Study 36103181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 34034790 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 40
Study 34034790 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 40
Study 32792102 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured diabetes education
Number of subjects: 3
Study 35694030 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (4000 mg daily)
Number of subjects: 20
Study 35694030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 34524394 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan for 3 years
Number of subjects: 4682098
Study 34034690 — intervention group
Group type: EXPERIMENTAL
Intervention: ADVANCE intervention + substance use treatment as usual (TAU), n=54
Number of subjects: 104
Study 34034690 — intervention group
Group type: COMPARATOR
Intervention: TAU only, n=50
Number of subjects: 104
Study 34034690 — intervention group
Group type: EXPERIMENTAL
Intervention: ADVANCE intervention
Number of subjects: 104
Study 616191660 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated AECT
Number of subjects: 18
Study 616191660 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine AECT
Number of subjects: 18
Study 616191660 — intervention group
Group type: COMPARATOR
Intervention: Compression Therapy (CT)
Number of subjects: 18
Study 33478480 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythritol air-polishing
Number of subjects: 20
Study 33478480 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrasonic/curette debridement
Number of subjects: 20
Study 33960119 — intervention group
Group type: EXPERIMENTAL
Intervention: mirabegron 50 mg QD
Number of subjects: 90
Study 33960119 — intervention group
Group type: EXPERIMENTAL
Intervention: solifenacin 5 mg QD
Number of subjects: 90
Study 33960119 — intervention group
Group type: COMPARATOR
Intervention: onabotulinumtoxinA only
Number of subjects: 90
Study 34519141 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerolizer® with 200 µg salbutamol
Number of subjects: 20
Study 34519141 — intervention group
Group type: EXPERIMENTAL
Intervention: Handihaler® with 200 µg salbutamol
Number of subjects: 20
Study 34519141 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal PIFR
Number of subjects: 20
Study 34519141 — intervention group
Group type: COMPARATOR
Intervention: Suboptimal PIFR
Number of subjects: 20
Study 32454458 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week after-school physical activity (PA) program
Number of subjects: 35
Study 32454458 — intervention group
Group type: COMPARATOR
Intervention: Sedentary attention control
Number of subjects: 35
Study 33948712 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib (8 mg/day for < 60 kg; 12 mg/day for ≥ 60 kg)
Number of subjects: 951
Study 33948712 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 951
Study 33948712 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 951
Study 36047646 — intervention group
Group type: EXPERIMENTAL
Intervention: STRATIFY + POCecho variable
Number of subjects: 84
Study 36047646 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPSE ≥ 17 mm plus STRATIFY
Number of subjects: 84
Study 36047646 — intervention group
Group type: EXPERIMENTAL
Intervention: Five right heart measures (TAPSE, TAPSE/PASP, TAPSE/RVDD, RV-FAC, fwRVLS)
Number of subjects: 84
Study 36047646 — intervention group
Group type: COMPARATOR
Intervention: STRATIFY alone
Number of subjects: 84
Study 34780022 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitors (dapagliflozin 10 mg or empagliflozin 10 mg)
Number of subjects: 0
Study 34780022 — intervention group
Group type: COMPARATOR
Intervention: Guideline-directed medical therapy
Number of subjects: 0
Study 34479930 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrorectus mesh augmentation with lightweight polypropylene mesh
Number of subjects: 470
Study 34479930 — intervention group
Group type: COMPARATOR
Intervention: Primary suture closure
Number of subjects: 470
Study 32496349 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram model based on independent prognostic factors (age, sex, T stage, N stage, bone metastasis) for predicting overall survival (OS)
Number of subjects: 0
Study 32496349 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram model for predicting 3-year OS
Number of subjects: 0
Study 32496349 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram model for predicting 5-year OS
Number of subjects: 0
Study 36151932 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-implant group
Number of subjects: 66
Study 36151932 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-implant group
Number of subjects: 66
Study 36151932 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 66
Study 32165547 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who had a stroke
Number of subjects: 7550
Study 32165547 — intervention group
Group type: COMPARATOR
Intervention: Patients who had not had a stroke (control group)
Number of subjects: 7550
Study 32165547 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke history
Number of subjects: 7550
Study 36114552 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Number of subjects: 60
Study 36114552 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 60
Study 33461488 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual factors (including physical, mental, and social characteristics)
Number of subjects: 3500
Study 33461488 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental factors (including social and material environment)
Number of subjects: 3500
Study 33033088 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive walking and education programme
Number of subjects: 349
Study 33033088 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 349
Study 33357008 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-deficit (ED) diet (1590 ± 79 kcal day‐1: 40% of total caloric omitted at lunchtime) with high-intensity cycling at 90% V˙O2peak
Number of subjects: 20
Study 33357008 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) group (2570 ± 139 kcal day‐1) with high-intensity cycling at 90% V˙O2peak
Number of subjects: 20
Study 35343449 — intervention group
Group type: EXPERIMENTAL
Intervention: PEKK double crown-retained RPDs
Number of subjects: 18
Study 35343449 — intervention group
Group type: COMPARATOR
Intervention: PEEK double crown-retained RPDs
Number of subjects: 18
Study 32343422 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised, structured, video-enhanced feedback and deliberate practice
Number of subjects: 0
Study 32343422 — intervention group
Group type: COMPARATOR
Intervention: Control group (experienced prescribers)
Number of subjects: 0
Study 33092415 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestin-primed ovarian stimulation (PPOS)
Number of subjects: 63
Study 33092415 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist (GnRH-A)
Number of subjects: 63
Study 34604251 — intervention group
Group type: EXPERIMENTAL
Intervention: Huashibaidu granule 10 g twice daily
Number of subjects: 408
Study 34604251 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 408
Study 34791324 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV-10
Number of subjects: 346
Study 34791324 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV-23
Number of subjects: 346
Study 34791324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 346
Study 34791324 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum vaccination
Number of subjects: 346
Study 34791324 — intervention group
Group type: EXPERIMENTAL
Intervention: Antepartum vaccination
Number of subjects: 346
Study 34791324 — intervention group
Group type: EXPERIMENTAL
Intervention: Postvaccination factors
Number of subjects: 346
Study 34791324 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotype 1 B- and T-cell memory
Number of subjects: 346
Study 33337109 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional energy drink (ED1) containing carbohydrates and 3 mg·kg‐1 of caffeine
Number of subjects: 12
Study 33337109 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-free energy drink (ED2) containing 3 mg·kg‐1 of caffeine
Number of subjects: 12
Study 33337109 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) - carbohydrate-containing, decaffeinated
Number of subjects: 12
Study 36181010 — intervention group
Group type: EXPERIMENTAL
Intervention: Codonopsis lanceolata water extract for 12 weeks
Number of subjects: 104
Study 36181010 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 104
Study 33418103 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic manual rotation
Number of subjects: 254
Study 33418103 — intervention group
Group type: COMPARATOR
Intervention: Sham rotation
Number of subjects: 254
Study 32429429 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod residual protein (Cod-RP) 8.1 g/day for eight weeks
Number of subjects: 50
Study 32429429 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control group)
Number of subjects: 50
Study 33856613 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (0-120 IU of NovoLog) with exercise
Number of subjects: 116
Study 33856613 — intervention group
Group type: COMPARATOR
Intervention: Intranasal insulin (0-120 IU of NovoLog) with sitting control
Number of subjects: 116
Study 36428075 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation based on the Transtheoretical Model (6-week program, 6 modules)
Number of subjects: 82
Study 36428075 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation based on the Transtheoretical Model
Number of subjects: 82
Study 32591295 — intervention group
Group type: EXPERIMENTAL
Intervention: HF nurse titration
Number of subjects: 320
Study 32591295 — intervention group
Group type: COMPARATOR
Intervention: HF cardiologist titration
Number of subjects: 320
Study 32307307 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV/Hib (Group A)
Number of subjects: 424
Study 32307307 — intervention group
Group type: COMPARATOR
Intervention: DTaP-IPV + Hib (Group B)
Number of subjects: 424
Study 32307307 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV/Hib (Group C, IM route)
Number of subjects: 424
Study 32307307 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV/Hib (Group A, Group C)
Number of subjects: 424
Study 36017158 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPT
Number of subjects: 401
Study 36017158 — intervention group
Group type: COMPARATOR
Intervention: IR-Tac/PR-Tac
Number of subjects: 401
Study 32854056 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly-victimization
Number of subjects: 100
Study 32854056 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly-deprivation
Number of subjects: 100
Study 34533193 — intervention group
Group type: EXPERIMENTAL
Intervention: 3U botulinum toxin type A injected at dilator naris anterior, dilator naris vestibularis, levator labii superioris alaeque nasi, and dilator naris
Number of subjects: 20
Study 34533193 — intervention group
Group type: EXPERIMENTAL
Intervention: 3U botulinum toxin type A
Number of subjects: 20
Study 34533193 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 20
Study 34533193 — intervention group
Group type: EXPERIMENTAL
Intervention: Root mean square analysis
Number of subjects: 20
Study 32894967 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill (hydrochlorothiazide 12.5 mg, aspirin 81 mg, atorvastatin 20 mg, and either enalapril 5 mg or valsartan 40 mg)
Number of subjects: 4415